# A Study Using Recombinant Human Chorionic Gonadotrophin (rhCG, Ovidrel®) in the Induction of Final Follicle Maturation and Early Luteinization in Chinese Women Undergoing in Vitro Fertilization and Embryo Transfer (IVF/ET)

> **NCT01081756** · PHASE3 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 218 (actual)

## Conditions studied

- Infertility

## Interventions

- **DRUG:** r-hCG
- **DRUG:** Urinary-hCG

## Key facts

- **NCT ID:** NCT01081756
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** —
- **Final completion:** 2004-09
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2014-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01081756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01081756, "A Study Using Recombinant Human Chorionic Gonadotrophin (rhCG, Ovidrel®) in the Induction of Final Follicle Maturation and Early Luteinization in Chinese Women Undergoing in Vitro Fertilization and Embryo Transfer (IVF/ET)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01081756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*